FT-873

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameFT-873

Drug Alias NameFT-873FT873FT 873

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionAnti-CD276Interleukin-7 receptor subunit alpha modulatorsImmunostimulants +[5]

TargetsCD276 antigenInterleukin-7 receptor subunit alphaLow affinity immunoglobulin gamma Fc region receptor III-A

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFate Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A